| Literature DB >> 25880648 |
Yumiko Kinoshita1, Akiko Chishaki2, Rieko Kawamoto3, Tatsuya Manabe4, Takashi Ueki5, Keiji Hirata6, Mami Miyazono7, Maki Kanaoka8, Akiko Tomioka9, Masahiro Nakano10, Tomoko Ohkusa11, Hisako Nakao12, Masao Tanaka13, Ryuichi Mibu14.
Abstract
BACKGROUND: Up to 80% of patients with rectal cancer undergo sphincter-saving surgery, and almost 90% of them experience subsequent physical changes. The number of studies on gender differences in response to this surgery has increased, and the connection between gender and symptoms and patient outcomes has generated increasing interest. Nevertheless, little is known about the gender differences in quality of life and cancer-related symptoms. We examined gender differences and quality of life changes over a 1-year period among patients with lower rectal cancer who were treated with sphincter-saving surgery.Entities:
Mesh:
Year: 2015 PMID: 25880648 PMCID: PMC4409720 DOI: 10.1186/s12957-015-0485-x
Source DB: PubMed Journal: World J Surg Oncol ISSN: 1477-7819 Impact factor: 2.754
Demographic and rectal cancer-related information ( = 75)
|
|
|
| |||
|---|---|---|---|---|---|
|
| 60.6 | (10.6) | 57.5 | (7.6) | 0.160 |
|
| |||||
| Employed full or part-time | 14 | 33.3 | 15 | 45.5 | 0.285 |
| Unemployed | 28 | 66.7 | 18 | 54.5 | |
|
| |||||
| Married | 41 | 97.6 | 32 | 97.0 | 1.000 |
| Other | 1 | 2.4 | 1 | 3.0 | |
|
| |||||
| No | 1 | 2.4 | 4 | 12.1 | 0.093 |
| Yes | 41 | 97.6 | 29 | 87.9 | |
|
| |||||
| I | 22 | 52.4 | 18 | 54.5 | 0.488 |
| II | 6 | 14.3 | 7 | 21.2 | |
| IIIa | 9 | 21.4 | 3 | 9.1 | |
| IIIb | 5 | 11.9 | 5 | 15.2 | |
|
| |||||
| ISR (temporary ileostomies) | 11 (11) | 26.2 | 5 (4) | 15.2 | 0.099 |
| ULAR (temporary ileostomies) | 16 (7) | 38.1 | 8 (2) | 24.2 | |
| LAR | 15 | 35.7 | 20 | 60.6 | |
|
| |||||
| No | 36 | 88.1 | 32 | 97.0 | 0.096 |
| Yes | 6 | 11.9 | 1 | 3.0 | |
|
| |||||
| No | 24 | 57.1 | 21 | 63.6 | 0.371 |
| Yes | 18 | 42.9 | 12 | 36.4 | |
|
| |||||
| No | 42 | 100.0 | 33 | 100.0 | 1.000 |
| Yes | 0 | 0.0 | 0 | 0.0 | |
Surgery: ISR intersphincteric resection, ULAR ultra-low anterior resection, LAR low anterior resection.
EORTC QLQ-C30v3 scores by time and gender ( = 75)
|
| ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
| |||||||||||||
|
|
|
|
|
|
|
|
|
|
| |||||||
|
|
|
|
|
|
|
|
|
| ||||||||
|
|
| |||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
|
|
|
|
|
|
|
|
|
|
| |||||||
|
| ||||||||||||||||
|
| 72.7 | 61.5 | 53.8 | 64.5 | 64.7 | 69.2 | 57.8 | 56.1 | 68.2 | 70.7 | <0.001 | 0.099 | 0.566 | 0.005 | 0.411 | 0.013 |
| 22.2 | 21.1 | 25.2 | 24.2 | 20.2 | 21.9 | 23.5 | 25.5 | 20.0 | 21.8 | T1 < T2** T1 < T3*** | ||||||
|
| ||||||||||||||||
| Physical functioning | 92.0 | 92.2 | 82.9 | 90.6 | 90.3 | 88.7 | 87.9 | 81.6 | 89.1 | 90.5 | <0.001 | 0.122 | 0.447 | 0.008 | 0.584 | 0.008 |
| 15.6 | 14.4 | 16.8 | 11.0 | 12.0 | 15.9 | 26.2 | 14.4 | 9.8 | 10.9 | T0 > T1** | ||||||
| T1 < T2** T1 < T3*** | ||||||||||||||||
| Role functioning | 89.8 | 84.5 | 63.5 | 75.4 | 76.6 | 86.6 | 77.8 | 57.6 | 79.8 | 84.3 | <0.001 | 0.209 | 0.997 | 0.000 | 0.060 | 0.036 |
| 21.7 | 20.6 | 30.4 | 27.4 | 23.3 | 23.7 | 27.2 | 30.1 | 19.0 | 19.1 | T0 > T1*** | ||||||
| T1 < T2*** T1 < T3*** | ||||||||||||||||
| Emotional functioning | 81.8 | 78.3 | 74.8 | 79.9 | 80.5 | 76.3 | 76.5 | 79.6 | 85.4 | 80.3 | 0.170 | 0.024 | 0.559 | 0.005 | 0.456 | 0.011 |
| 18.8 | 20.6 | 25.3 | 19.9 | 18.8 | 22.2 | 18.3 | 24.6 | 14.1 | 23.7 | |||||||
| Cognitive functioning | 92.7 | 83.7 | 78.0 | 79.4 | 78.2 | 90.1 | 81.3 | 83.8 | 82.8 | 85.4 | 0.845 | 0.003 | 0.339 | 0.013 | 0.130 | 0.026 |
| 15.0 | 17.8 | 23.0 | 18.3 | 20.3 | 18.4 | 19.9 | 18.4 | 18.8 | 17.1 | |||||||
| Social functioning | 92.0 | 77.8 | 65.3 | 73.4 | 73.4 | 90.3 | 77.3 | 68.7 | 82.3 | 85.9 | <0.001 | 0.094 | 0.187 | 0.024 | 0.141 | 0.025 |
| 18.3 | 27.2 | 29.9 | 24.7 | 23.9 | 20.1 | 25.3 | 25.2 | 20.4 | 20.0 | T0 > T1* | At 12 months after surgery: men < women | |||||
| T1 < T2** T1 < T3** | ||||||||||||||||
|
| ||||||||||||||||
| Fatigue | 14.0 | 23.3 | 35.6 | 22.8 | 23.8 | 19.5 | 28.3 | 35.7 | 29.0 | 25.9 | <0.001 | 0.090 | 0.290 | 0.015 | 0.632 | 0.007 |
| 0.3 | 18.3 | 23.5 | 16.3 | 17.6 | 23.1 | 21.7 | 20.7 | 16.9 | 20.5 | T0 < T1* | ||||||
| T1 > T2** T1 > T3* | ||||||||||||||||
| Nausea and vomiting | 1.8 | 0.8 | 3.6 | 1.2 | 1.6 | 3.6 | 3.0 | 6.6 | 3.5 | 3.0 | 0.063 | 0.038 | 0.163 | 0.026 | 0.860 | 0.002 |
| 7.6 | 3.6 | 10.8 | 4.3 | 6.2 | 11.4 | 8.8 | 18.1 | 10.0 | 7.7 | |||||||
| Pain | 13.0 | 14.7 | 26.2 | 16.3 | 17.1 | 17.2 | 20.2 | 18.7 | 16.2 | 11.6 | 0.064 | 0.035 | 0.649 | 0.003 | 0.148 | 0.025 |
| 23.1 | 21.5 | 29.9 | 24.0 | 25.4 | 25.3 | 23.5 | 20.7 | 23.4 | 18.4 | |||||||
| Dyspnea | 6.9 | 12.2 | 8.1 | 8.1 | 7.3 | 9.1 | 9.1 | 7.1 | 6.1 | 10.1 | 0.455 | 0.012 | 0.784 | 0.001 | 0.616 | 0.080 |
| 18.5 | 24.5 | 16.3 | 20.8 | 15.8 | 21.6 | 17.2 | 20.0 | 13.1 | 15.6 | |||||||
| Insomnia | 13.0 | 23.0 | 31.8 | 22.2 | 26.2 | 19.1 | 27.3 | 31.3 | 28.3 | 25.3 | 0.301 | 0.016 | 0.681 | 0.002 | 0.741 | 0.005 |
| 24.4 | 29.9 | 31.2 | 32.7 | 35.0 | 29.0 | 29.4 | 35.3 | 30.2 | 23.6 | |||||||
| Appetite loss | 4.2 | 6.4 | 10.3 | 7.2 | 3.2 | 6.3 | 17.2 | 29.3 | 16.2 | 12.1 | 0.005 | 0.064 | 0.002 | 0.130 | 0.346 | 0.015 |
| 14.0 | 13.3 | 26.6 | 18.8 | 9.9 | 17.4 | 27.8 | 35.1 | 27.8 | 20.1 | T1 > T3** | Men < Women | |||||
| Constipation | 2.5 | 28.6 | 28.4 | 23.0 | 23.0 | 4.3 | 35.4 | 26.3 | 33.3 | 28.3 | 0.467 | 0.011 | 0.296 | 0.015 | 0.485 | 0.011 |
| 11.8 | 32.6 | 30.9 | 29.9 | 32.5 | 14.9 | 36.3 | 27.3 | 25.0 | 22.3 | |||||||
| Diarrhea | 2.5 | 23.0 | 23.4 | 22.2 | 23.0 | 3.1 | 23.2 | 24.2 | 20.2 | 14.1 | 0.402 | 0.013 | 0.504 | 0.006 | 0.448 | 0.012 |
| 10.4 | 25.0 | 26.3 | 21.7 | 22.7 | 12.6 | 22.8 | 25.4 | 26.3 | 18.7 | |||||||
| Financial difficulties | 5.5 | 17.5 | 28.8 | 19.8 | 22.2 | 6.3 | 13.1 | 24.2 | 15.2 | 16.2 | 0.007 | 0.057 | 0.336 | 0.013 | 0.989 | <0.001 |
| 17.8 | 29.7 | 26.4 | 25.6 | 30.1 | 18.6 | 24.9 | 33.6 | 23.7 | 26.5 | T0 < T1* T1 > T2** | ||||||
Higher scores on functional scales and overall QOL scale indicate higher levels of function. Higher scores on symptoms scales or single items (#) indicate higher levels of symptoms or problems.
*P < 0.05; **P < 0.01; ***P < 0.001.
EORTC QLQ-CR38 scores by time and gender
|
|
|
|
| |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
| |||||||||||||
|
|
|
|
|
|
|
| ||||||||
|
|
|
|
|
|
|
|
|
| ||||||
|
|
|
|
|
|
| |||||||||
|
|
|
|
|
|
|
|
|
|
|
| ||||
|
|
|
|
|
|
|
|
| |||||||
|
| ||||||||||||||
| Body image | 85.2 | 71.6 | 80.4 | 78.8 | 82.2 | 75.8 | 76.4 | 81.8 | 0.006 | 0.064 | 0.992 | 0.001 | 0.298 | 0.017 |
| 15.3 | 27.9 | 17.7 | 17.5 | 21.9 | 26.7 | 23.4 | 20.4 | T0 > T1* | ||||||
| T1 < T2** T1 < T3** | ||||||||||||||
| Future perspective | 60.3 | 55.4 | 61.1 | 62.7 | 55.6 | 45.5 | 57.6 | 62.6 | 0.025 | 0.045 | 0.281 | 0.016 | 0.634 | 0.007 |
| 25.8 | 34.8 | 26.5 | 26.8 | 28.5 | 33.2 | 19.2 | 21.7 | T1 < T3* | ||||||
| Sexual functioning | 21.8 | 18.7 | 21.0 | 14.7 | 14.3 | 4.2 | 7.1 | 7.7 | 0.009 | 0.059 | 0.002 | 0.133 | 0.146 | 0.024 |
| 21.6 | 19.6 | 17.7 | 14.8 | 19.1 | 9.8 | 15.3 | 16.7 | T0 > T3* | Men > Women | |||||
| Sexual enjoyment | 47.6 | 28.6 | 33.3 | 23.8 | 33.3 | 22.2 | 44.4 | 33.3 | 0.272 | 0.147 | 0.434 | 0.106 | 1.000 | 0.001 |
| 26.2 | 29.9 | 27.2 | 25.2 | 22.5 | 19.3 | 19.3 | 22.5 | |||||||
|
| ||||||||||||||
| Micturition problems | 19.1 | 37.2 | 24.6 | 22.8 | 10.1 | 26.3 | 19.2 | 15.8 | < 0.001 | 0.171 | 0.014 | 0.080 | 0.668 | 0.006 |
| 21.7 | 27.5 | 17.1 | 17.2 | 12.5 | 21.1 | 17.6 | 15.5 | T0 < T1*** T0 < T2* | Men > Women | |||||
| T1 > T2* T1 > T3** | ||||||||||||||
| Gastrointestinal tract symptoms | 16.7 | 24.7 | 15.7 | 17.1 | 24.4 | 28.3 | 21.6 | 17.0 | 0.012 | 0.055 | 0.163 | 0.027 | 0.495 | 0.010 |
| 19.3 | 20.1 | 12.9 | 15.7 | 27.6 | 30.0 | 14.8 | 2.5 | T1 > T2* T1 > T3* | ||||||
| Defecation problems | 19.7 | 36.1 | 26.8 | 24.3 | 19.7 | 30.9 | 21.7 | 17.4 | < 0.001 | 0.205 | 0.055 | 0.051 | 0.383 | 0.014 |
| 15.3 | 18.1 | 11.4 | 15.6 | 14.0 | 14.5 | 11.2 | 11.0 | T0 < T1*** | ||||||
| T1 > T2*** T1 > T3*** | ||||||||||||||
| Weight loss | 9.5 | 24.6 | 5.5 | 5.6 | 11.1 | 23.2 | 14.1 | 14.1 | < 0.001 | 0.116 | 0.168 | 0.026 | 0.289 | 0.017 |
| 18.5 | 28.6 | 12.6 | 12.6 | 16.0 | 28.2 | 26.4 | 23.6 | T0 < T1** | ||||||
| T1 > T2*** T1 > T3*** | ||||||||||||||
Higher scores on functional scales and overall QOL scale represent higher levels of functioning. Higher score on symptoms scales or single items (#) indicate higher levels of symptoms or problems.
*P < 0.05; **P < 0.01; ***P < 0.001.
Correlations between global health status/QOL scores and functional and symptom scales of EORTC QLQ-C30
|
| ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
| |||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||
| Men | R | 0.306 | 0.484 | 0.733 | 0.334 | 0.726 | −0.604 | −0.070 | −0.479 | −0.351 | −0.561 | −0.258 | −0.270 | −0.168 | −0.528 | |
| Before Surgery |
| 0.049 | 0.001 | <0.001 | 0.031 | <0.001 | <0.001 | 0.658 | 0.001 | 0.023 | <0.001 | 0.099 | 0.084 | 0.287 | <0.001 | |
| Women | R | 0.543 | 0.680 | 0.779 | 0.516 | 0.646 | −0.710 | −0.017 | −0.418 | −0.283 | −0.303 | −0.365 | −0.093 | −0.393 | −0.482 | |
|
| 0.001 | <0.001 | <0.001 | 0.002 | <0.001 | <0.001 | 0.927 | 0.015 | 0.111 | 0.087 | 0.037 | 0.607 | 0.024 | 0.005 | ||
| 1 month after surgery | Men | R | 0.603 | 0.709 | 0.741 | 0.555 | 0.659 | −0.642 | −0.238 | −0.656 | −0.309 | −0.524 | −0.465 | −0.082 | −0.324 | −0.336 |
|
| <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | 0.129 | <0.001 | 0.046 | <0.001 | 0.002 | 0.608 | 0.036 | 0.029 | ||
| Women | R | 0.561 | 0.579 | 0.680 | 0.342 | 0.658 | −0.784 | −0.175 | −0.354 | −0.018 | −0.669 | −0.590 | −0.099 | −0.183 | −0.436 | |
|
| 0.002 | <0.001 | <0.001 | 0.052 | <0.001 | <0.001 | 0.329 | 0.043 | 0.920 | <0.001 | <0.001 | 0.583 | 0.307 | 0.011 | ||
| 6 months after surgery | Men | R | 0.650 | 0.672 | 0.479 | 0.548 | 0.525 | −0.692 | −0.082 | −0.589 | −0.252 | −0.456 | −0.249 | −0.414 | −0.109 | −0.365 |
|
| <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | 0.608 | <0.001 | 0.107 | 0.002 | 0.112 | 0.006 | 0.490 | 0.017 | ||
| Women | R | 0.374 | 0.308 | 0.304 | 0.106 | 0.313 | −0.611 | −0.132 | −0.168 | −0.179 | −0.290 | −0.294 | −0.176 | −0.031 | −0.314 | |
|
| 0.032 | 0.081 | 0.085 | 0.558 | 0.077 | 0.001 | 0.464 | 0.350 | 0.319 | 0.102 | 0.097 | 0.326 | 0.864 | 0.076 | ||
| 12 months after surgery | Men | R | 0.650 | 0.672 | 0.479 | 0.548 | 0.525 | −0.692 | −0.082 | −0.589 | −0.252 | −0.456 | −0.249 | −0.414 | −0.109 | −0.365 |
|
| <0.001 | <0.001 | 0.001 | <0.001 | <0.001 | <0.001 | 0.608 | <0.001 | 0.107 | 0.002 | 0.112 | 0.006 | 0.490 | 0.017 | ||
| Women | R | 0.469 | 0.328 | 0.338 | 0.335 | 0.532 | −0.601 | −0.405 | −0.128 | −0.053 | −0.404 | −0.470 | −0.137 | −0.091 | −0.567 | |
|
| 0.006 | 0.063 | 0.054 | 0.057 | 0.001 | <0.001 | 0.019 | 0.478 | 0.771 | 0.020 | 0.006 | 0.447 | 0.614 | 0.002 | ||
Correlations between global health status/QOL scores and functional and symptom scales of EORTC QLQ-CR38
|
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
|
| |||||||||
|
|
|
|
|
|
|
|
| |||
| Before Surgery | Men | R | 0.674 | 0.699 | 0.222 | 0.200 | −0.137 | −0.422 | −0.349 | −0.288 |
|
| <0.001 | <0.001 | 0.158 | 0.397 | 0.387 | 0.005 | 0.025 | 0.064 | ||
| Women | R | 0.585 | 0.167 | 0.144 | 0.546 | −0.182 | −0.377 | −0.206 | −0.355 | |
|
| 0.001 | 0.354 | 0.455 | 0.129 | 0.312 | 0.031 | 0.266 | 0.043 | ||
| 1 month after surgery | Men | R | 0.565 | 0.685 | 0.240 | 0.575 | −0.241 | −0.528 | −0.527 | −0.568 |
|
| <0.001 | <0.001 | 0.125 | 0.025 | 0.124 | <0.001 | <0.001 | 0.001 | ||
| Women | R | 0.602 | 0.543 | 0.063 | 0.278 | −0.166 | −0.437 | −0.430 | −0.330 | |
|
| <0.001 | 0.001 | 0.733 | 0.594 | 0.357 | 0.011 | 0.012 | 0.061 | ||
| 6 months after surgery | Men | R | 0.450 | 0.501 | 0.193 | 0.281 | −0.311 | −0.393 | −0.538 | −0.159 |
|
| 0.003 | 0.002 | 0.221 | 0.072 | 0.045 | 0.010 | <0.001 | 0.315 | ||
| Women | R | 0.205 | 0.247 | 0.549 | 0.415 | −0.136 | −0.083 | −0.082 | −0.100 | |
|
| 0.252 | 0.165 | 0.001 | 0.016 | 0.452 | 0.644 | 0.650 | 0.582 | ||
| 12 months after surgery | Men | R | 0.450 | 0.501 | 0.193 | 0.281 | −0.311 | −0.393 | −0.538 | −0.159 |
|
| 0.003 | 0.002 | 0.221 | 0.072 | 0.045 | 0.010 | <0.001 | 0.315 | ||
| Women | R | 0.352 | 0.469 | 0.211 | 0.218 | −0.470 | −0.213 | −0.235 | −0.154 | |
|
| 0.044 | 0.006 | 0.247 | 0.230 | 0.006 | 0.234 | 0.188 | 0.391 | ||
Males (n = 42), females (n = 33). Higher scores on functional scales and overall QOL scale indicate higher levels of functioning. Higher scores on symptoms scale or single items (#) indicate higher levels of symptoms or problems.
Figure 1Regression predicting global health status/QOL in men and women. Higher scores on the functional scales and overall QOL scale indicate higher levels of function. Higher scores on the symptoms scales or single items (#) indicate higher levels of symptoms or problems. *P < 0.05; **P < 0.01; ***P < 0.001.
Figure 2Regression predicting social functioning at 12 months after surgery in men and women. Higher scores on the functional scales and overall QOL scale indicate higher levels of function. Higher scores on the symptoms scales or single items (#) indicate higher levels of symptoms or problems. *P < 0.05; **P < 0.01; ***P < 0.001.